NewAmsterdam Pharma Company N.V.NAMSNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +1490.54% | +112.56% | +740.06% | -98.80% | -99.75% |
| Gross Profit Growth | +1490.54% | +112.56% | +740.06% | -98.80% | -100.21% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +17.64% | +41.34% | +18.79% | +25.59% | +17.90% |
| Weighted Average Shares Diluted Growth | +17.64% | +41.34% | +18.79% | +25.59% | +17.90% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +293.49% | +8.67% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +149.10% | +67.55% | +82.48% | +79.06% | -11.03% |
| Book Value per Share Growth | +123.27% | +33.56% | +69.15% | +53.02% | -23.48% |
| Debt Growth | +646.67% | +804.65% | -41.64% | -47.43% | -54.91% |
| R&D Expense Growth | -15.49% | +5.47% | -28.30% | -13.25% | +10.60% |
| SG&A Expenses Growth | +179.24% | +87.86% | +78.22% | +41.92% | +12.54% |